Table 5.
Variation in biological parameters between one-year follow-up and allocation.
| SPA arm (n = 55) | CTR arm (n = 49) | p value effect of | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≤25 | 25–30 | >30 | ≤25 | 25–30 | >30 | SPA | Time | BMI | ||
| (n = 29) | (n = 15) | (n = 11) | (n = 23) | (n = 19) | (n = 7) | |||||
| Glucose | mmol/l | 0.007 ± 0.446 | 0.459 ± 0.748 | 0.749 ± 1.358 | −0.089 ± 0.326 | 0.226 ± 0.394 | 1.75 ± 2.775 | 0.23 | 0.04 | <10–6 |
| (0.6%) | (8.9%) | (15.9%) | (−1.6%) | (4.4%) | (25.9%) | |||||
| HDL-cholesterol | mmol/l | −0.438 ± 1.471 | −0.241 ± 1.34 | −0.542 ± 1.31 | −0.436 ± 1.384 | −0.333 ± 1.635 | −0.028 ± 0.198 | 0.41 | 0.027 | 0.007 |
| (−5.6%) | (3.4%) | (−13%) | (−4.8%) | (7%) | (−1.3%) | |||||
| Transthyretin | g/l | 0.001 ± 0.038 | 0.009 ± 0.026 | −0.005 ± 0.027 | 0.001 ± 0.033 | −0.007 ± 0.031 | 0.002 ± 0.051 | 0.041 | 0.75 | 0.79 |
| (1%) | (3.5%) | (−1.5%) | (0.8%) | (−2%) | (3.2%) | |||||
| C-reactive protein | mg/l | −0.146 ± 1.142 | 0.238 ± 2.818 | −0.127 ± 1.481 | 0.264 ± 1.168 | −0.135 ± 4.736 | −1 ± 5.545 | 0.11 | 0.73 | <10–7 |
| (11.1%) | (27.3%) | (8.9%) | (41.8%) | (41.1%) | (−6.6%) | |||||
| Insulin | mUI/l | 0.17 ± 3.79 | 1.97 ± 4.59 | 2.51 ± 10.19 | 0.22 ± 6.58 | 4.47 ± 10.51 | 4.53 ± 6.24 | 0.41 | 0.035 | <10–7 |
| (25.7%) | (115.7%) | (58.4%) | (36.1%) | (50.9%) | (78.4%) | |||||
| IGF-1 | μg/l | −0.79 ± 27.51 | −26.61 ± 27.25 | −18.78 ± 23.9 | −13.18 ± 39.9 | −12.41 ± 34.83 | 9.13 ± 16.55 | 0.32 | 0.072 | 0.31 |
| (6.3%) | (−19.7%) | (−24%) | (−4.2%) | (−12.2%) | (16.5%) | |||||
| Leptin | μg/l | −0.03 ± 1.57 | −0.02 ± 2.72 | −2.42 ± 6.24 | 0.12 ± 2.38 | 1.64 ± 6.28 | −0.93 ± 3.78 | 0.66 | 0.81 | <10–7 |
| (15.6%) | (9%) | (−2.4%) | (21.7%) | (23.6%) | (−7.4%) | |||||
| Adiponectin | mg/l | 2.33 ± 4.19 | 1.29 ± 2.3 | 0.57 ± 1.3 | 0.99 ± 2.51 | 1.15 ± 2.65 | 0.65 ± 1.01 | 0.33 | 0.082 | 0.022 |
| (32.6%) | (17.3%) | (18%) | (13.9%) | (11.5%) | (5.6%) | |||||
| Leptin/adiponectin ratio | −0.1 ± 0.27 | −0.08 ± 0.52 | −1.68 ± 2.92 | 0.13 ± 1.21 | 1.2 ± 4.07 | −0.27 ± 0.29 | 0.73 | 0.91 | 2 × 10–6 | |
| (−2.9%) | (−0.4%) | (−18%) | (24.2%) | (16.6%) | (−13.6%) | |||||
| Testosterone | nmol/l | −0.033 ± 0.299 | −0.013 ± 0.098 | 0.045 ± 0.347 | −0.051 ± 0.244 | 0.015 ± 0.332 | 0.029 ± 0.757 | 0.086 | 0.83 | 0.27 |
| (−3.6%) | (5%) | (10.7%) | (−5%) | (3.4%) | (21.8%) | |||||
| CA 15-3 | kU/l | 2.32 ± 3.08 | 0.62 ± 1.78 | 0.27 ± 1.71 | −5.32 ± 28.45 | 1.56 ± 2.06 | 2.71 ± 1.48 | 0.04 | 0.68 | 0.07 |
| (18.2%) | (6.8%) | (4.7%) | (1.4%) | (12.5%) | (14%) | |||||
Variation for each parameter is expressed in raw value (one-year follow-up value minus allocation value) and in percentage of the allocation value: + sign indicates an increase and – sign indicates a decrease. Two-way ANOVA was used to compare longitudinal variations between allocation arms (SPA effect), or one-year follow-up (time effect), or BMI groups (BMI effect), but without interaction test because of unequal class sizes. All tests were two-sided, and the nominal level of significance was 5%. Significant p values are indicated in bold.